vs

Side-by-side financial comparison of CuriosityStream Inc. (CURI) and TriSalus Life Sciences, Inc. (TLSI). Click either name above to swap in a different company.

CuriosityStream Inc. is the larger business by last-quarter revenue ($19.2M vs $13.2M, roughly 1.5× TriSalus Life Sciences, Inc.). CuriosityStream Inc. runs the higher net margin — -19.7% vs -73.9%, a 54.1% gap on every dollar of revenue. On growth, TriSalus Life Sciences, Inc. posted the faster year-over-year revenue change (59.8% vs 35.8%). CuriosityStream Inc. produced more free cash flow last quarter ($3.9M vs $-2.5M). Over the past eight quarters, TriSalus Life Sciences, Inc.'s revenue compounded faster (43.0% CAGR vs 26.5%).

Curiosity Stream Inc., formerly branded as CuriosityStream, is an American media company and over-the-top subscription video streaming service which offers documentary programming including films, series, and TV shows. The company offers a video on demand subscription service branded as "Curiosity Stream" and a linear broadcast television channel known as the Curiosity Channel through various services including FuboTV and The Roku Channel.

TriSalus Life Sciences, Inc. is a clinical-stage biotechnology company focused on advancing immuno-oncology and interventional oncology solutions. It develops proprietary targeted drug delivery technologies designed to improve treatment efficacy for patients with liver, pancreatic and other hard-to-treat solid tumors, primarily operating in North American markets via partnerships with clinical care and research institutions.

CURI vs TLSI — Head-to-Head

Bigger by revenue
CURI
CURI
1.5× larger
CURI
$19.2M
$13.2M
TLSI
Growing faster (revenue YoY)
TLSI
TLSI
+24.0% gap
TLSI
59.8%
35.8%
CURI
Higher net margin
CURI
CURI
54.1% more per $
CURI
-19.7%
-73.9%
TLSI
More free cash flow
CURI
CURI
$6.5M more FCF
CURI
$3.9M
$-2.5M
TLSI
Faster 2-yr revenue CAGR
TLSI
TLSI
Annualised
TLSI
43.0%
26.5%
CURI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CURI
CURI
TLSI
TLSI
Revenue
$19.2M
$13.2M
Net Profit
$-3.8M
$-9.8M
Gross Margin
86.7%
Operating Margin
-17.6%
-24.8%
Net Margin
-19.7%
-73.9%
Revenue YoY
35.8%
59.8%
Net Profit YoY
-34.6%
3.5%
EPS (diluted)
$-0.07
$-0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CURI
CURI
TLSI
TLSI
Q4 25
$19.2M
$13.2M
Q3 25
$18.4M
$11.6M
Q2 25
$19.0M
$11.2M
Q1 25
$15.1M
$9.2M
Q4 24
$14.1M
$8.3M
Q3 24
$12.6M
$7.3M
Q2 24
$12.4M
$7.4M
Q1 24
$12.0M
$6.5M
Net Profit
CURI
CURI
TLSI
TLSI
Q4 25
$-3.8M
$-9.8M
Q3 25
$-3.7M
$-10.8M
Q2 25
$784.0K
$-8.3M
Q1 25
$319.0K
$-10.4M
Q4 24
$-2.8M
$-10.1M
Q3 24
$-3.1M
$-2.4M
Q2 24
$-2.0M
$-4.3M
Q1 24
$-5.0M
$-13.2M
Gross Margin
CURI
CURI
TLSI
TLSI
Q4 25
86.7%
Q3 25
83.5%
Q2 25
83.9%
Q1 25
83.7%
Q4 24
85.3%
Q3 24
86.3%
Q2 24
87.6%
Q1 24
85.0%
Operating Margin
CURI
CURI
TLSI
TLSI
Q4 25
-17.6%
-24.8%
Q3 25
-24.5%
-77.9%
Q2 25
2.5%
-65.4%
Q1 25
0.5%
-79.9%
Q4 24
-27.4%
-91.8%
Q3 24
-25.8%
-118.9%
Q2 24
-20.6%
-111.0%
Q1 24
-30.4%
-180.8%
Net Margin
CURI
CURI
TLSI
TLSI
Q4 25
-19.7%
-73.9%
Q3 25
-20.4%
-93.5%
Q2 25
4.1%
-73.9%
Q1 25
2.1%
-113.2%
Q4 24
-19.9%
-122.4%
Q3 24
-24.3%
-32.6%
Q2 24
-16.4%
-58.8%
Q1 24
-42.0%
-204.5%
EPS (diluted)
CURI
CURI
TLSI
TLSI
Q4 25
$-0.07
$-0.22
Q3 25
$-0.06
$-0.96
Q2 25
$0.01
$-0.27
Q1 25
$0.01
$-0.39
Q4 24
$-0.05
$-0.38
Q3 24
$-0.06
$-0.12
Q2 24
$-0.04
$-0.21
Q1 24
$-0.09
$-0.60

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CURI
CURI
TLSI
TLSI
Cash + ST InvestmentsLiquidity on hand
$27.3M
$20.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$41.5M
$-33.9M
Total Assets
$75.7M
$35.3M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CURI
CURI
TLSI
TLSI
Q4 25
$27.3M
$20.4M
Q3 25
$27.8M
$22.7M
Q2 25
$28.1M
$26.5M
Q1 25
$33.4M
$13.0M
Q4 24
$32.1M
$8.5M
Q3 24
$33.2M
$11.3M
Q2 24
$39.5M
$16.5M
Q1 24
$38.8M
$4.0M
Stockholders' Equity
CURI
CURI
TLSI
TLSI
Q4 25
$41.5M
$-33.9M
Q3 25
$47.2M
$-26.7M
Q2 25
$49.8M
$-19.4M
Q1 25
$58.1M
$-34.4M
Q4 24
$57.8M
$-25.9M
Q3 24
$62.2M
$-20.4M
Q2 24
$64.8M
$-25.3M
Q1 24
$67.0M
$-36.0M
Total Assets
CURI
CURI
TLSI
TLSI
Q4 25
$75.7M
$35.3M
Q3 25
$74.7M
$36.5M
Q2 25
$78.7M
$41.3M
Q1 25
$85.3M
$28.6M
Q4 24
$86.2M
$24.0M
Q3 24
$87.6M
$27.5M
Q2 24
$90.9M
$32.4M
Q1 24
$94.6M
$17.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CURI
CURI
TLSI
TLSI
Operating Cash FlowLast quarter
$4.0M
$-2.5M
Free Cash FlowOCF − Capex
$3.9M
$-2.5M
FCF MarginFCF / Revenue
20.5%
-19.1%
Capex IntensityCapex / Revenue
0.1%
0.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-19.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CURI
CURI
TLSI
TLSI
Q4 25
$4.0M
$-2.5M
Q3 25
$4.4M
$-3.7M
Q2 25
$2.8M
$-7.3M
Q1 25
$1.9M
$-4.5M
Q4 24
$3.0M
$-5.7M
Q3 24
$2.3M
$-10.8M
Q2 24
$2.2M
$-13.4M
Q1 24
$666.0K
$-10.9M
Free Cash Flow
CURI
CURI
TLSI
TLSI
Q4 25
$3.9M
$-2.5M
Q3 25
$-3.9M
Q2 25
$-7.4M
Q1 25
$1.8M
$-5.3M
Q4 24
$-5.8M
Q3 24
$-11.0M
Q2 24
$-13.5M
Q1 24
$-10.9M
FCF Margin
CURI
CURI
TLSI
TLSI
Q4 25
20.5%
-19.1%
Q3 25
-33.9%
Q2 25
-66.1%
Q1 25
12.2%
-57.3%
Q4 24
-69.7%
Q3 24
-149.9%
Q2 24
-183.1%
Q1 24
-169.3%
Capex Intensity
CURI
CURI
TLSI
TLSI
Q4 25
0.1%
0.3%
Q3 25
0.0%
1.9%
Q2 25
0.0%
0.8%
Q1 25
0.5%
8.2%
Q4 24
0.0%
0.6%
Q3 24
0.0%
2.3%
Q2 24
0.0%
0.8%
Q1 24
0.0%
1.0%
Cash Conversion
CURI
CURI
TLSI
TLSI
Q4 25
Q3 25
Q2 25
3.56×
Q1 25
6.03×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons